Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections caused by AmpC β-lactamase-producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens : a pilot multicenter randomized controlled trial (MERINO-2)

Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections caused by AmpC β-lactamase-producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens : a pilot multicenter randomized controlled trial (MERINO-2)

Background: Carbapenems are recommended treatment for serious infections caused by AmpC-producing gram-negative bacteria but can select for carbapenem resistance. Piperacillin-tazobactam may be a suitable alternative. Methods We enrolled adult patients with bloodstream infection due to chromoso...

Full description

Bibliographic Details
Main Authors: Stewart, Adam G., Paterson, David L., Young, Barnaby, Lye, David C., Davis, Joshua S., Schneider, Kellie, Yilmaz, Mesut, Dinleyici, Rumeysa, Runnegar, Naomi, Henderson, Andrew, Archuleta, Sophia, Kalimuddin, Shirin, Forde, Brian M., Chatfield, Mark D., Bauer, Michelle J., Lipman, Jeffrey, Harris-Brown, Tiffany, Harris, Patrick N. A.
Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
Format: Journal Article
Language:English
Published: 2021
Subjects:
Science::Medicine
Carbapenem
Clinical Trial
Online Access:https://hdl.handle.net/10356/154068

Internet

https://hdl.handle.net/10356/154068

Similar Items